Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities
- 18 October 2005
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 228 (1-2) , 181-186
- https://doi.org/10.1016/j.canlet.2004.11.065
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Drug Delivery Systems: Entering the MainstreamScience, 2004
- Disseminated Neuroblastoma in Children Older Than One Year at Diagnosis: Comparable Results With Three Consecutive High-Dose Protocols Adopted by the Italian Co-Operative Group for NeuroblastomaJournal of Clinical Oncology, 2003
- Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatmentCancer Letters, 2003
- Ligand-targeted therapeutics in anticancer therapyNature Reviews Cancer, 2002
- Antisense therapy in oncology: new hope for an old idea?The Lancet, 2001
- A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stabilityBiochimica et Biophysica Acta (BBA) - Biomembranes, 2000
- Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In VivoThe Journal of Immunology, 2000
- Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B CellsThe Journal of Immunology, 2000
- Molecular Biology of NeuroblastomaJournal of Clinical Oncology, 1999
- Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancerGene Therapy, 1997